MX2015015015A - Metodo para diagnosticar cancer. - Google Patents

Metodo para diagnosticar cancer.

Info

Publication number
MX2015015015A
MX2015015015A MX2015015015A MX2015015015A MX2015015015A MX 2015015015 A MX2015015015 A MX 2015015015A MX 2015015015 A MX2015015015 A MX 2015015015A MX 2015015015 A MX2015015015 A MX 2015015015A MX 2015015015 A MX2015015015 A MX 2015015015A
Authority
MX
Mexico
Prior art keywords
diagnosing cancer
cancer
cd95l
expression
diagnosing
Prior art date
Application number
MX2015015015A
Other languages
English (en)
Other versions
MX363679B (es
Inventor
Christian Gieffers
Harald Fricke
Jaromir Sykora
Original Assignee
Apogenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh filed Critical Apogenix Gmbh
Publication of MX2015015015A publication Critical patent/MX2015015015A/es
Publication of MX363679B publication Critical patent/MX363679B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona con un método para diagnosticar una enfermedad por cáncer, que comprende (a) determinar la expresión de CD95L en una muestra de cáncer, y (b) clasificar la enfermedad de cáncer de acuerdo con el nivel de expresión de CD95L.
MX2015015015A 2013-04-29 2014-04-29 Metodo para diagnosticar cancer. MX363679B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165784 2013-04-29
PCT/EP2014/058746 WO2014177576A1 (en) 2013-04-29 2014-04-29 Method of diagnosing cancer

Publications (2)

Publication Number Publication Date
MX2015015015A true MX2015015015A (es) 2016-07-21
MX363679B MX363679B (es) 2019-03-29

Family

ID=48190325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015015A MX363679B (es) 2013-04-29 2014-04-29 Metodo para diagnosticar cancer.

Country Status (9)

Country Link
US (1) US20160103132A1 (es)
EP (1) EP2992330B1 (es)
JP (1) JP6556121B2 (es)
CN (1) CN105393121B (es)
AU (1) AU2014261505B2 (es)
BR (1) BR112015027249A2 (es)
CA (1) CA2910332A1 (es)
MX (1) MX363679B (es)
WO (1) WO2014177576A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2877989C (en) 2012-07-18 2021-05-25 Apogenix Gmbh Shortened cd95-fc variants
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
EP3076179A1 (en) * 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
WO2017009429A1 (en) * 2015-07-14 2017-01-19 Apogenix Ag Method of predicting the responsiveness of a cancer disease to treatment
WO2023099578A1 (en) * 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing anti-cd95l monoclonal antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505348A (ja) * 1999-07-16 2003-02-12 マキシム ファーマシューティカルス，インコーポレイテッド 反応性酸素代謝産物阻害剤を用いた細胞傷害性リンパ球の活性化および防御
CN100335121C (zh) * 2001-07-20 2007-09-05 得克萨斯大学体系董事会 涉及hpv相关的癌前期的和癌的生长(包括cin)的方法和组合物
WO2003027242A2 (en) * 2001-09-24 2003-04-03 Duke University Fas ligand
PT1490405E (pt) * 2002-03-21 2007-11-07 Lilly Co Eli Anticorpos humanos anti-ligando de hfas antagonistas e fragmentos dos mesmos
EP2089711B1 (en) * 2006-11-10 2012-09-12 Alphaptose Gmbh Methods and compositions for detecting receptor ligand mimetics
AU2007341631B9 (en) * 2006-12-28 2012-10-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
US20090234202A1 (en) * 2008-03-05 2009-09-17 Goix Philippe J Method and compositions for highly sensitive detection of molecules
US11369572B2 (en) * 2009-07-21 2022-06-28 Queen Mary & Westfield College Fas (Apo-1,CD95) targeted platforms for intracellular drug delivery
EP2742154A4 (en) * 2011-08-08 2015-08-12 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
CA2877989C (en) * 2012-07-18 2021-05-25 Apogenix Gmbh Shortened cd95-fc variants

Also Published As

Publication number Publication date
CA2910332A1 (en) 2014-11-06
AU2014261505B2 (en) 2019-04-18
BR112015027249A2 (pt) 2017-09-26
US20160103132A1 (en) 2016-04-14
WO2014177576A1 (en) 2014-11-06
JP6556121B2 (ja) 2019-08-07
JP2016524694A (ja) 2016-08-18
MX363679B (es) 2019-03-29
CN105393121B (zh) 2018-04-24
EP2992330B1 (en) 2018-04-18
EP2992330A1 (en) 2016-03-09
AU2014261505A1 (en) 2015-11-12
CN105393121A (zh) 2016-03-09

Similar Documents

Publication Publication Date Title
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EP3064940A4 (en) Salivary biomarker for cancer, method and device for assaying same, and method for determining salivary biomarker for cancer
MX340453B (es) Biomarcadores para cancer de pulmon.
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
NZ629555A (en) Monocyte biomarkers for cancer detection
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
SG11201504874QA (en) Sample analysis for mass cytometry
MX2019005748A (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
BR112014025520A2 (pt) método para estimar características de uma formação
EP3011055A4 (en) Classification system, methods and kit for classifying. predicting and treating breast cancer
EP2947458A4 (en) PROCESS FOR THE IMMUNOLOGICAL DETERMINATION OF HEMOGLOBIN-A1C IN SAMPLES
ITRM20120383A1 (it) Metodo e kit per la rivelazione di anticorpi.
EP2971132A4 (en) FABRIC AND BLOOD-BASED MIRNA BIOMARKERS FOR THE DIAGNOSIS, FORECASTING AND PREDICTING THE METASTAS POTENTIAL IN COLOR LECTAL CANCER
EP3176268A4 (en) Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof
MX2015015452A (es) Metodo y sistema para evaluar una condicion de salud.
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
MX353954B (es) Aptameros y metodos de diagnostico para detectar el receptor del factor de crecimiento epidermal (egf).
EP2951852A4 (en) SYSTEMS AND METHODS FOR ANALYZING A SAMPLE EXTRACT
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX363679B (es) Metodo para diagnosticar cancer.
EP2962105A4 (en) METHODS AND REAGENTS FOR DETERMINING ISOMERIC ANALYTES
EP2972321A4 (en) REAGENTS, SYSTEMS AND METHODS FOR ANALYZING WHITE GLOBLES
EP3122906A4 (en) Hpv16 antibodies as diagnostic and prognostic biomarkers in pre-invasive and invasive disease